Skip to main content
Premium Trial:

Request an Annual Quote

OncoSolutions Taps CollabRx to Provide Variant Interpretation Services

Premium

NEW YORK (GenomeWeb) – CollabRx said this week that Singapore-based private oncology firm OncoSolutions Cancer Center has signed a multi-year agreement to use CollabRx's Genetic Variant Annotation (GVA) service to analyze tumor genetic data.

The OncoSolutions deal is CollabRx's "first such commercial relationship with a private oncology company," Thomas Mika, chairman, president and CEO of CollabRx, noted in a statement. He added the agreement also expands the company's presence in Asia.

Financial and other terms of the agreement were not disclosed.

CollabRx launched GVA last year to provide variant interpretation services to the clinical laboratory research market including hospital labs, research institutions and academic medical centers. The service pairs the results of genetic sequencing tests with clinically actionable information such as the impact of specific genetic profiles and associated therapeutic strategies – drugs and clinical trials – that can be used to inform patient treatment.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.